AI assistant
Laurus Labs Limited — Call Transcript 2021
Oct 21, 2021
62639_rns_2021-10-21_98d17ca1-cf73-478e-9f84-fc3676076569.pdf
Call Transcript
Open in viewerOpens in your device viewer
==> picture [114 x 37] intentionally omitted <==
LAURUS LABS LIMITED
LAURUS LABS LTD. Q2 FY22 RESULTS CONFERENCE CALL ON FRIDAY, OCTOBER 29, 2021 AT 11:00 AM IST
Laurus Labs Ltd. (Laurus), a leading research and development driven pharmaceutical company in India, will organize a conference call for Investors and Analysts, on Friday, October 29, 2021 at 11:00 am IST .
The conference call will be initiated with a brief management discussion on the Q2 FY22 results, followed by an interactive Question & Answer session. The call will be hosted by Ambit Capital.
Details of the conference call are as follows:
For Diamond pass please Copy this URL in your browser:
| Timing | 11:00 am IST on October 29, 2021 |
|---|---|
| Conference dial-in | |
| PrimaryNumber | +91 22 6280 1148 |
| SecondaryNumber | +91 22 7115 8049_Available all over India_ |
| Singapore | 800 101 2045 |
| HongKong | 800 964 448 |
| USA | 1 866 746 2133 |
| UK | 0 808 101 1573 |
==> picture [139 x 54] intentionally omitted <==
OCTOBER 21, 2021
PAGE 2
==> picture [113 x 36] intentionally omitted <==
About Laurus Labs Ltd.
Laurus Labs is a fully integrated pharmaceutical and biotechnology company, with a leadership position in generic Active Pharmaceutical Ingredients /(APIs) and a major focus on anti-retroviral, Hepatitis C, and oncology drugs. We also develop and manufacture oral solid formulations, provide contract research and manufacturing services (CRAMS) to Global pharma companies, and produce specialty ingredients for nutraceuticals, dietary supplements and cosmeceuticals.
We are passionate about advanced chemistry skills. Our proven expertise in bringing innovative solution, manufacturing efficiencies and unwavering quality focus has won us long-standing relationship with our global customers. Laurus employs 4800+ people, including around 750+ scientists at more than 8 facilities approved by major regulatory agencies USFDA, WHO-Geneva, UK-MHRA etc. During FY2021 Laurus generated over Rs4,800 crore in annual revenue and is listed on the BSE (formerly Bombay Stock Exchange) and the NSE (National Stock Exchange) in India. Laurus' proactive stance to conduct business with utmost Transparency, Integrity and Respect for environment & communities have earned it a place in Governance benchmark, Certified Great Place to Work and Rated “A” by leading MSCI ESG Ratings. For more information visit www.lauruslabs.com
Corporate Identification No: L24239AP2005PLC047518
For further information, please contact
Vivek Kumar Laurus Labs Limited Tel: +91 40 6659 4366 Email: [email protected]
OCTOBER 21, 2021